Guardant Health Total Cost of Revenue increased by 5.5% to $104.92M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 40.4%, from $74.72M to $104.92M. Over 2 years (FY 2023 to FY 2025), Total Cost of Revenue shows an upward trend with a 24.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $56.76M | $56.76M | $56.76M | $56.76M | $65.30M | $72.42M | $74.49M | $77.59M | $74.72M | $81.21M | $93.59M | $99.49M | $104.92M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +15.0% | +10.9% | +2.9% | +4.2% | -3.7% | +8.7% | +15.2% | +6.3% | +5.5% |
| YoY Change | — | — | — | — | +15.0% | +27.6% | +31.2% | +36.7% | +14.4% | +12.1% | +25.6% | +28.2% | +40.4% |
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 |
|---|---|---|---|---|
| Reportable Segment | $72.19M | $78.30M | $90.87M | $101.56M |
| Total | $74.72M | $81.21M | $93.59M | $104.92M |